ACRIA was one site in a multicenter study of NGX-4010, a skin patch for pain due to HIV-related neuropathy.

It was hoped that the patch would relieve pain due to HIV-related neuropathy (pain affecting the nerves in the feet and hands). This study of 494 patients was blinded, so people used a patch containing NGX-4010, or a control patch (containing a very small amount of NGX-4010) for either 30 or 60 minutes.

Unfortunately, the study found that the NGX-4010 patch did not perform better than the control patch. The 30-minute NGX-4010 group had a 26.1% reduction in pain compared to 19.1% for the control group, and the 60-minute NGX-4010 group had a 32.8% reduction in pain compared to 30.1% for the control group. These results were not statistically significant (meaning they could be due to chance).